<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CAPECITABINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CAPECITABINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Stage III colon cancer, adjuvant following surgery (monotherapy)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1.25 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability&#8212;consult product literature.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Stage III colon cancer, adjuvant following surgery (combination therapy)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.8&#8211;1 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, recommended duration of treatment is 6 months, adjust dose according to tolerability&#8212;consult product literature.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Metastatic colcorectal cancer (monotherapy)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1.25 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability&#8212;consult product literature.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Metastatic colorectal cancer (combination therapy)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.8&#8211;1 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability&#8212;consult product literature.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Advanced gastric cancer (first-line treatment in combination with a platinum based regimen)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                0.8&#8211;1 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, alternatively 625 mg/m2 twice daily given continuously, adjust dose according to tolerability&#8212;consult product literature.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Locally advanced or metastatic breast cancer (second-line treatment as monotherapy after failure of a taxane and anthracycline regimen or where further anthracycline treatment is not indicated)</span>,
                <span class="indication">Locally advanced or metastatic breast cancer (second-line treatment, in combination with docetaxel, where previous therapy included an anthracycline)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                1.25 g/m2 twice daily for 14 days, subsequent courses repeated after a 7-day interval, adjust dose according to tolerability&#8212;consult product literature.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Capecitabine is metabolised to fluorouracil.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid (teratogenic in <i>animal</i> studies).</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Manufacturer advises monitor liver function in mild to moderate impairment&#8212;consult product literature for guidance on treatment interruption; avoid in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Reduce starting dose of 1.25&#8239;g/m<sup>2</sup> to 75% if creatinine clearance 30&#8211;50&#8239;mL/minute.</p>
            </section>
        
            <section class="generalInformation">
              <p>Avoid if creatinine clearance less than 30&#8239;mL/minute.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Dihydropyrimidine dehydrogenase deficiency</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>notKnown:</strong> Alopecia, bone-marrow suppression, hyperuricaemia, nausea, oral mucositis, thromboembolism, tumour lysis syndrome, vomiting,
              </p>
        
        
            <section class="advice">
              <p>For further information on side-effects, consult product literature.</p>
            </section>
        
      </section>



      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA61</h3>
              <p outputclass="title">Capecitabine and tegafur with uracil for metastatic colorectal cancer (May 2003)</p> <p>Capecitabine or tegafur with uracil [now discontinued] (in combination with folinic acid) is an option for the first-line treatment of metastatic colorectal cancer.</p><xref format="html" href="http://www.nice.org.uk/TA61">www.nice.org.uk/TA61</xref>
                <a href="http://www.nice.org.uk/TA61" target="_blank">www.nice.org.uk/TA61</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA100</h3>
              <p outputclass="title">Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes&#8217; C) colon cancer (April 2006)</p> <p>Capecitabine alone <i>or</i> oxaliplatin combined with fluorouracil and folinic acid are options for adjuvant treatment following surgery for stage III (Dukes&#8217; C) colon cancer.</p><xref format="html" href="http://www.nice.org.uk/TA100">www.nice.org.uk/TA100</xref>
                <a href="http://www.nice.org.uk/TA100" target="_blank">www.nice.org.uk/TA100</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA191</h3>
              <p outputclass="title">Capecitabine for the treatment of advanced gastric cancer (July 2010)</p> <p>Capecitabine in combination with a platinum-based regimen is recommended for the first-line treatment of inoperable advanced gastric cancer.</p><xref format="html" href="http://www.nice.org.uk/TA191">www.nice.org.uk/TA191</xref>
                <a href="http://www.nice.org.uk/TA191" target="_blank">www.nice.org.uk/TA191</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA212</h3>
              <p outputclass="title">Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)</p> <p>Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine is <b>not</b> recommended for the treatment of metastatic colorectal cancer.</p><xref format="html" href="http://www.nice.org.uk/TA212">www.nice.org.uk/TA212</xref>
                <a href="http://www.nice.org.uk/TA212" target="_blank">www.nice.org.uk/TA212</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA263</h3>
              <p outputclass="title">Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012)</p> <p>Bevacizumab in combinations with capecitabine is <b>not</b> recommended within its marketing authorisation for the first-line treatment of metastatic breast cancer, that is, when treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate, or when taxanes or anthracyclines have been used as part of adjuvant treatment in the previous 12 months.</p><xref format="html" href="http://www.nice.org.uk/TA263">www.nice.org.uk/TA263</xref>
                <a href="http://www.nice.org.uk/TA263" target="_blank">www.nice.org.uk/TA263</a>
            </section>
      </section>

      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Risks of incorrect dosing of oral anti-cancer medicines</h3>
              <p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy. Standards to be followed to achieve this include:</p><ul>
            <li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>
            <li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>
            </ul>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Diabetes mellitus
          </li>
          <li>
            diarrhoea or dehydration&#8212;consult product literature for guidance on dose modification and treatment interruption
          </li>
          <li>
            electrolyte disturbances
          </li>
          <li>
            history of angina pectoris
          </li>
          <li>
            history of arrhythmias
          </li>
          <li>
            history of significant cardiovascular disease
          </li>
          <li>
            nervous system disease
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended).</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency).</p><p>Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause.</p><p>No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
                <h3>Severe skin reactions</h3>
              <p>Monitor for symptoms of severe skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis)&#8212;permanently discontinue treatment immediately if symptoms occur.</p>
            </section>
            <section class="patientParameters">
                <h3>Hand-foot syndrome</h3>
              <p>Monitor for symptoms of hand-foot syndrome&#8212;interrupt treatment if significant syndrome occurs and refer to product literature.</p>
            </section>
            <section class="patientParameters">
              <p>Monitor plasma-calcium concentration.</p><p>Monitor for eye disorders (including keratitis and corneal disorders).</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CAPECITABINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76147"><a href="../medicinalForm/PHP76147.html" data-target="#PHP76147" data-action="load">Tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
